{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:23:55Z","timestamp":1792783435636,"version":"4.5.0"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T00:00:00Z","timestamp":1792540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"ViiV Healthcare","id":[{"id":"https:\/\/ror.org\/01cc9yk21","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"DOI":"10.1007\/s12325-026-03812-z","type":"journal-article","created":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:50:41Z","timestamp":1792594241000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Safety and Effectiveness of Dolutegravir\/Rilpivirine in Japanese People Living with HIV: Final Report of 6-Year Post-marketing Surveillance Study"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-8616-8835","authenticated-orcid":false,"given":"Akemi","family":"Sebata","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1154-7090","authenticated-orcid":false,"given":"Takako","family":"Nagao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Matsukawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-5027-250X","authenticated-orcid":false,"given":"Yoichiro","family":"Yoshikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5855-2084","authenticated-orcid":false,"given":"Akiko","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,21]]},"reference":[{"key":"3812_CR1","unstructured":"Joint United Nations Programme on HIV\/AIDS. The urgency of now: AIDS at a crossroads. 2024. https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2024-unaids-global-aids-update_en.pdf. Accessed 28 June 2026."},{"key":"3812_CR2","unstructured":"AIDS Prevention Information Network. AIDS incidence trend annual report 2024. [in Japanese]. https:\/\/api-net.jfap.or.jp\/status\/japan\/nenpo2024.html. Accessed 28 June 2026."},{"key":"3812_CR3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1001\/jama.2024.24543","volume":"333","author":"RT Gandhi","year":"2024","unstructured":"Gandhi RT, Landovitz RJ, Sax PE, et al. Antiretroviral drugs for treatment and prevention of HIV in adults: 2024 recommendations of the International Antiviral Society-USA Panel. JAMA. 2024;333:609\u201328.","journal-title":"JAMA"},{"key":"3812_CR4","unstructured":"ViiV Healthcare K.K. and GlaxoSmithKline K.K. Juluca Combination Tablets [package insert] [in Japanese]. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/6250115. Accessed 28 June 2026."},{"key":"3812_CR5","unstructured":"ViiV Healthcare K.K. and GlaxoSmithKline K.K. Tivicay Tablets [package insert] [in Japanese]. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/6250038. Accessed 28 June 2026."},{"key":"3812_CR6","unstructured":"ViiV Healthcare K.K. and GlaxoSmithKline K.K. Triumeq Combination Tablets [package insert] [in Japanese]. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/6250106. Accessed 28 June 2026."},{"key":"3812_CR7","unstructured":"ViiV Healthcare K.K. and GlaxoSmithKline K.K. Dovato Combination Tablets [package insert] [in Japanese]. https:\/\/www.pmda.go.jp\/PmdaSearch\/iyakuDetail\/GeneralList\/6250119. Accessed 28 June 2026."},{"key":"3812_CR8","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(17)33095-7","volume":"391","author":"JM Llibre","year":"2018","unstructured":"Llibre JM, Hung CC, Brinson C, et al. Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase\u00a03, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 2018;391:839\u201349.","journal-title":"Lancet"},{"key":"3812_CR9","doi-asserted-by":"publisher","first-page":"e576","DOI":"10.1016\/S2352-3018(19)30149-3","volume":"6","author":"M Aboud","year":"2019","unstructured":"Aboud M, Orkin C, Podzamczer D, et al. Efficacy and safety of dolutegravir-rilpivirine for maintenance of virological suppression in adults with HIV-1: 100-week data from the randomised, open-label, phase\u00a03 SWORD-1 and SWORD-2 studies. Lancet HIV. 2019;6:e576\u201387.","journal-title":"Lancet HIV"},{"key":"3812_CR10","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1097\/QAI.0000000000002449","volume":"85","author":"J van Wyk","year":"2020","unstructured":"van Wyk J, Orkin C, Rubio R, et al. Brief report: durable suppression and low rate of virologic failure 3\u00a0years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and SWORD-2 randomized clinical trials. J Acquir Immune Defic Syndr. 2020;85:325\u201330.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"3812_CR11","unstructured":"CMIC Co., Ltd. HIV related drugs cooperative survey [in Japanese]. https:\/\/www.hrd.gr.jp\/index.html. Accessed 28 June 2026."},{"key":"3812_CR12","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1007\/s12325-026-03544-0","volume":"43","author":"A Sebata","year":"2026","unstructured":"Sebata A, Nagao T, Matsukawa T, et al. Safety and effectiveness analysis of dolutegravir and dolutegravir\/abacavir\/lamivudine in Japanese people living with HIV: 10\u00a0years of post-marketing surveillance. Adv Ther. 2026;43:2527\u201349.","journal-title":"Adv Ther"},{"key":"3812_CR13","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1097\/QCO.0000000000000616","volume":"33","author":"AR Eckard","year":"2020","unstructured":"Eckard AR, McComsey GA. Weight gain and integrase inhibitors. Curr Opin Infect Dis. 2020;33:10\u20139.","journal-title":"Curr Opin Infect Dis"},{"key":"3812_CR14","unstructured":"Ministry of Health, Labour and Welfare. The anti-HIV treatment guidelines 2026 [in Japanese]. https:\/\/hiv-guidelines.jp\/pdf\/hiv_guideline2026.pdf. Accessed 28 June 2026."},{"key":"3812_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1007\/s40121-024-00961-y","volume":"13","author":"S Schneider","year":"2024","unstructured":"Schneider S, Blick G, Burke C, et al. Two-drug regimens dolutegravir\/lamivudine and dolutegravir\/rilpivirine are effective with few discontinuations in US real-world settings: results from the TANDEM study. Infect Dis Ther. 2024;13:891\u2013906.","journal-title":"Infect Dis Ther"},{"key":"3812_CR16","doi-asserted-by":"publisher","DOI":"10.3390\/v15040936","volume":"15","author":"C Duenas-Gutierrez","year":"2023","unstructured":"Duenas-Gutierrez C, Buzon L, Pedrero-Tome R, et al. Efficacy and safety of two-drug regimens with dolutegravir plus rilpivirine or lamivudine in HIV-1 virologically suppressed people living with HIV. Viruses. 2023;15:936.","journal-title":"Viruses"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03812-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03812-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03812-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T14:50:42Z","timestamp":1792594242000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03812-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,21]]},"references-count":16,"alternative-id":["3812"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03812-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,21]]},"assertion":[{"value":"8 July 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Akemi Sebata, Takako Nagao, Tomoko Matsukawa, Yoichiro Yoshikawa, and Akiko Fukuda, and Dong Wang are employed by ViiV Healthcare K.K.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This post-marketing surveillance study was conducted by CMIC HOLDINGS Co., Ltd. on behalf of ViiV Healthcare K.K. in compliance with the relevant Japanese regulations (Ministerial Ordinance on GPSP; MHLW No. 171 of December 20, 2004, the amended ordinance, and the related notifications). The study protocol was reviewed and approved by the Pharmaceuticals and Medical Devices Agency, the Japanese regulatory authority, and subsequently approved by the ethics committee at each participating institution. Under the GPSP regulations, written informed consent from participants is not required for post-marketing surveillance studies.","order":2,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}